Biofrontera (NASDAQ:BFRI) Announces Quarterly Earnings Results

Biofrontera (NASDAQ:BFRI) announced its quarterly earnings data on Thursday. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.29), FiscalAI reports. The business had revenue of $10.08 million during the quarter, compared to the consensus estimate of $10.25 million. Biofrontera had a negative net margin of 25.26% and a negative return on equity of 1,236.11%.

Here are the key takeaways from Biofrontera’s conference call:

• Biofrontera reported Q1 2026 product revenue of $10.1 million, up 17% year over year, driven by a 16% increase in Ameluz tube volume and a price increase implemented in late 2025.
• The new post-transaction cost structure materially improved profitability, with gross margin expanding to about 80% from 62% a year ago and management saying the company is tracking toward its 80%-85% long-term target.
• Cash used in operations was just $70,000 in the quarter, a sharp improvement from $4.1 million in Q1 2025, which management said supports its path to cash flow breakeven this year.
• The clinical/regulatory pipeline advanced on multiple fronts, including FDA acceptance of the supplemental NDA for superficial basal cell carcinoma with a PDUFA date of September 28, 2026, and positive phase III data for AK on the neck, trunk, and extremities supporting a planned sNDA filing in Q3 2026.
• Management also highlighted encouraging phase II acne data and said it expects to discuss a potential phase III program with the FDA later in 2026, while noting ongoing tariff and supply-chain monitoring because all products are imported from Europe.

Biofrontera Stock Performance

Shares of NASDAQ BFRI traded up $0.03 during midday trading on Thursday, hitting $0.99. The company’s stock had a trading volume of 401,633 shares, compared to its average volume of 375,182. The firm has a market capitalization of $11.89 million, a price-to-earnings ratio of -0.96 and a beta of 0.89. The company has a current ratio of 1.52, a quick ratio of 1.40 and a debt-to-equity ratio of 0.44. The stock has a fifty day moving average price of $0.97 and a 200 day moving average price of $0.90. Biofrontera has a one year low of $0.54 and a one year high of $1.19.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings raised shares of Biofrontera from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, April 27th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $2.75.

Institutional Investors Weigh In On Biofrontera

A hedge fund recently raised its stake in Biofrontera stock. Geode Capital Management LLC grew its stake in shares of Biofrontera Inc. (NASDAQ:BFRI) by 54.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 65,677 shares of the company’s stock after acquiring an additional 23,074 shares during the period. Geode Capital Management LLC owned 0.56% of Biofrontera worth $37,000 at the end of the most recent reporting period. 10.08% of the stock is owned by institutional investors and hedge funds.

About Biofrontera

Biofrontera AG is a specialty biopharmaceutical company focused on the research, development and commercialization of products for dermatological applications. The company’s core expertise lies in photodynamic therapy (PDT), a treatment modality that uses a photosensitizing agent activated by a specific light source to target diseased skin cells while sparing surrounding healthy tissue.

The flagship product in Biofrontera’s portfolio is Ameluz (aminolevulinic acid hydrochloride 10 % gel), which has received marketing approval in the European Union for treatment of actinic keratosis and basal cell carcinoma, and in the United States for actinic keratosis.